Navigation Links
Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
Date:3/10/2010

Collaboration Exploits Cellzome's World-Leading Proteomics Technology in Epigenetics

CAMBRIDGE, England and HEIDELBERG, Germany, March 10, 2010 /PRNewswire/ -- Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

Under the terms of the agreement, the companies will work together using Cellzome's Episphere(TM) technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies will share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.

Under the financial terms, Cellzome will receive an upfront payment of EUR33 million, comprising technology access fees and the purchase of equity. In addition, Cellzome is eligible for milestone payments and tiered royalties for each programme. Milestone payments under this collaboration could reach over EUR475 million if all programmes under the alliance are successfully developed and commercialised.

Tim Edwards, Chief Executive Officer of Cellzome, said: "We are delighted to form another major alliance with GSK, using our leading technology and people to find transformative medicines in this exciting field of biology. Combining forces with GSK will accelerate the development of new anti-inflammatory drugs for the benefit of patients."

About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called Episphere(TM) to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

In addition to the alliance with GSK in the field of epigenetics, Cellzome has another strategic alliance with GSK to discover, develop and market kinase-targeted therapeutics to treat inflammatory disease and an alliance with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: http://www.cellzome.com.

About Episphere(TM) and epigenetics

Episphere(TM) is a chemical proteomics technology for the discovery of novel drugs directed against targets involved in epigenetic regulation. The technology allows the screening and profiling of inhibitors of epigenetic targets in their native environment, directly in the lysate of cells and tissues and can also differentiate between the complexes these targets operate in. The term epigenetics refers to heritable changes in gene expression and phenotype caused by mechanisms other than changes in DNA sequence. One major mechanism is the specific enzymatic modification of histone tails, which affects the packaging of DNA into chromatin and through that controls the transcription of specific genes. Enzymes, such as histone deacetylases (HDAC) or methyltransferases (HMT) can change the modification of the histone tails and therefore change the 'histone code'. Dysregulation of these modifications is thought to play a central role in cancer and in chronic degenerative diseases like neurological and autoimmune disease. The enzymes which carry out these histone modifications are part of large multifunctional protein complexes, which represent attractive novel targets for drug discovery.

SOURCE Cellzome

Back to top
'/>"/>
SOURCE Cellzome
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
2. Micromet Announces Proposed Public Offering of Common Stock
3. Orthopaedic Synergy, Inc. Announces Letter of Intent to Acquire Praxim, SA.
4. MiMedx Group Announces Addition of Sales Director for Europe
5. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
6. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
7. INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
8. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Microfluidics Announces Two New Board Members
11. Lexicon Announces Proposed $95 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the ... to honor the victims of the Holocaust and Nazi persecution, Center for Medicine ... and Auschwitz on its CMATH Champions trip to Germany and Poland next week. , ...
(Date:4/24/2017)... ... 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... during the April 22-23 event at the San Mateo Event Center. , In ... care, CDA Cares educates the public and policymakers about the importance of good oral ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a company ... its popular products are now available for purchase on StackedNutrition.com, a popular website ... of premium natural ingredients in making all of its products. These ingredients come ...
Breaking Medicine News(10 mins):